Compare WB & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WB | OGN |
|---|---|---|
| Founded | 2009 | 1923 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2014 | 2020 |
| Metric | WB | OGN |
|---|---|---|
| Price | $6.37 | $13.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 5 |
| Target Price | $8.24 | ★ $11.25 |
| AVG Volume (30 Days) | 883.9K | ★ 2.1M |
| Earning Date | 11-17-2026 | 11-09-2026 |
| Dividend Yield | ★ 9.44% | 0.58% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.95 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $0.11 | N/A |
| Revenue Next Year | $0.78 | $2.51 |
| P/E Ratio | ★ $5.66 | $14.47 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.37 | $5.69 |
| 52 Week High | $12.77 | $13.79 |
| Indicator | WB | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 53.63 |
| Support Level | N/A | $13.46 |
| Resistance Level | $6.79 | $13.77 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 25.00 | 62.50 |
Weibo Corp is a China-based company that operates a social media platform for people to create, discover and distribute content. The company currently operates and manages its business in two principal business lines globally - advertising and marketing services and value-added services. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The company's main product is the social platform Weibo. It generates a substantial majority of its revenues from online advertising and marketing services.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.